Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by DavidKingCanadaon Jul 05, 2021 11:37am
102 Views
Post# 33492820

RE:RE:RE:RE:RE:Share Price vs Market Cap

RE:RE:RE:RE:RE:Share Price vs Market CapTB, two days later you wrote the following which is a complete turn around;

---
You are correct for the first time, I do not invest in penny stocks and am a deivative specialist. So for you who do not know what that entails, here is an example. Buy 100,000 shares of Merck and sell the September 18, $75.00 calls, net return to investor 11%. Constant returns is where the big money stays. I have one person who asked me to do an analysis on this little Biotech and i see this is a very useless board and weak management team. Your only saving grace will be your Chief Doctor who seems to have hit the correct scientific sequence. Your Company is froth with redundant Directors as i previously mentioned. Like it or not I really do not care.
---

<< Previous
Bullboard Posts
Next >>